Propylene glycol-free melphalan hydrochloride (DrugBank: Melphalan, Propylene glycol)
15 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
11 | Myasthenia | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
14 | Chronic inflammatory demyelinating polyneuropathy | 0 |
19 | Lysosomal storage disease | 0 |
20 | Adrenoleukodystrophy | 0 |
28 | Systemic amyloidosis | 1 |
60 | Aplastic anemia | 0 |
62 | Paroxysmal nocturnal hemoglobinuria | 0 |
65 | Primary immunodeficiency | 0 |
96 | Crohn disease | 0 |
164 | Oculocutaneous albinism | 0 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02994784 (ClinicalTrials.gov) | January 8, 2018 | 18/11/2016 | Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients | A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation | Amyloidosis; Systemic | Drug: Propylene Glycol-Free Melphalan Hydrochloride | Boston Medical Center | Spectrum Pharmaceuticals, Inc | Recruiting | 18 Years | N/A | All | 43 | Phase 2 | United States |